“I am delighted to welcome a strong and experienced commercial leader like Erik to Glycorex. Erik brings extensive global commercial expertise to the organization from his work at companies like SSI Diagnostica, Euro Diagnostica AB (now Svar), DAKO and Olympus. He will continue to build the commercial team and expand the distribution channels for our products,” said Geert Nygaard, Chief Executive Officer of Glycorex Transplantation.

“I look very much forward to joining the Glycorex team,” Mr. Pedersen said. “I am convinced by the quality of the products as proven in clinical use over many years and the potential of the unique technology. My immediate focus will be to expand the commercial reach for our Glycosorb® ABO and UBP products, as well as enhancing our sales and marketing capabilities”.

Mr. Pedersen will take on his responsibilities as per April 1st, 2022.


Geert Nygaard, CEO, Glycorex Transplantation AB.

E-mail: info@glycorex.se, phone: 046-286 52 30

This information is such information that Glycorex Transplantation AB is required to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication on January 17, 2022 at XX.XX CET.

Brief information about the company

Glycosorb® ABO is one of Glycorex Transplantation AB's self-developed proprietary medical devices that is used clinically in four continents to facilitate blood group-compatible transplants, especially in kidney transplants from related living donors, but the product is also used in liver, heart, lung and stem cell transplantation. The product has so far been used in more than 5,000 kidney transplants. The short-term and long-term results are excellent. The results have been presented in over 60 scientific articles in reputable medical journals. Each kidney transplant has been estimated to save up to SEK 5 million in dialysis costs alone. Each kidney transplant saves about 150 dialysis treatments per year, meaning that the over 5,000 kidney transplants performed after Glycosorb® treatments, can be estimated to save over 700,000 dialysis treatments per year. In addition to Europe, the product is used in India, Canada, Israel, Singapore, Thailand, Mexico and Australia, for example.

The company has also developed a CE-marked medical device for the development of universal blood plasma and are developing products for the specific reduction of autoantibodies in the treatment of autoimmune diseases, as well as products for specific reduction of galectins. The company also develops products for the simultaneous reduction of blood group A/B specific antibodies and HLA antibodies (tissue-specific antibodies). The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis. There are approximately 5 million patients in the EU who have this disease.

Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.